跳到正文
原文
MedPage Today·· 7 天前AI 评分41

Beyond Diagnosis 系列访谈:晚期前列腺癌转移灶管理与放疗角色

Managing Metastases in Advanced Prostate Cancer

AI 导读

Cleveland Clinic肿瘤学家 Christopher Wee 与主持人 John Mangels 探讨晚期前列腺癌转移灶的综合管理策略。系统治疗仍是基础,但 STAMPEDE 试验显示低负荷转移性激素敏感性前列腺癌患者接受前列腺靶向放疗可获生存获益;寡进展时可考虑 SBRT 以避免立即换药。

正文

— Beyond Diagnosis continues with Christopher Wee on radiation therapy and multidisciplinary care

November 12, 2026 • 6 min read

Our Partner logo

Developed in partnership with the Our Partner

In "Beyond Diagnosis: Metastatic Castration-Sensitive Prostate Cancer," Cleveland Clinic oncologist Christopher Wee, MD, and host John Mangels discuss how clinicians can guide patients through the growing complexities of treatment for metastatic disease.

Each installment of this series explores key moments in patient care, including building trust, navigating evolving therapies, aligning treatment goals, and supporting shared decision-making.

In this fourth episode, Wee discusses the role of radiation in managing metastatic disease, strategies for treating bone metastases and preventing skeletal complications, and the importance of multidisciplinary care in balancing disease control with quality of life.

The following is a transcript of their remarks:

Mangels: Welcome to "Beyond Diagnosis," where we talk with doctors about treatment decisions and communicating with patients. I'm your host, John Mangels.

Treatment of metastatic castration-sensitive prostate cancer has changed significantly in the last decade. Those changes are creating new opportunities and new complexities for both physicians and patients. How do clinicians choose among expanded treatment options? How do they navigate decisions involving efficacy and risk, quality of life, and patient preferences?

We'll explore those issues and more with our guest, Dr. Christopher Wee. Dr. Wee is a physician in Cleveland Clinic's genitourinary medical oncology program. A large part of his practice involves patients with prostate cancer. Dr. Wee, thanks so much for joining us today.

Wee: Thank you for having me.

Mangels: Metastatic disease involves more complexities and more complications potentially than localized prostate cancer. Is your approach to treat metastases individually? Do you try and control them systemically? What's your approach on that?

Wee: Historically, metastatic disease has been a systemic therapy situation, because the spots that you can see on imaging likely underrepresent the true burden of disease. There could be micrometastases elsewhere. And so that's why we don't go and necessarily go after each individual metastasis.

However, there's a caveat, and this is an evolving science. Radiation is becoming an integral part in certain situations. So if someone were to have low-volume de novo metastatic hormone-sensitive prostate cancer, there is a survival benefit per the STAMPEDE trial to do prostate-directed radiotherapy. Sometimes we'll even consider metastasis-directed therapy in those situations. And then if something were to become oligoprogressive to castrate-resistant, so let's say someone has castration-sensitive prostate cancer, metastatic, and the PSA [prostate-specific antigen] starts rising, but there's only one or two spots that are really lighting up on a repeat PET, there are emerging data suggesting that radiation or often SBRT [stereotactic body radiotherapy] can be a benefit to that patient because then if they can get control, they don't have to necessarily switch treatment.

So this is evolving science. I think this is where it's very important to have a multidisciplinary team evaluate these situations, but systemic therapy is still the backbone of treatment of metastatic disease.

Mangels: We've talked a lot already about patient communication. When patients learn that their prostate cancer has spread to their bones or say an organ like the liver, that's bound to be frightening to them. How do you help them understand what those findings mean without completely eradicating hope?

Wee: I think it's frightening because of the uncertainty, and I wish I could sometimes give more certainty to patients like this. Most patients want an honest answer. They don't want sugarcoating. So I'll ask a patient, "Do you mind if I'm upfront with you?" Vast majority of the time they want to know. This is generally considered, in historically speaking, not a curable situation, but some patients can live for years, many years. I don't know at this point. Our goal is to try to give you the best outcome possible, and we do this with these treatments and we go from there.

If patients start asking more specifically about life expectancies, again, at the time of metastatic diagnosis, the median overall survival is years. So it's really hard to predict at that point what this is going to look like.

Mangels: And that's so important to emphasize that incurable doesn't mean untreatable.

Wee: Correct.

Mangels: And then I'm guessing the discussion about patient treatment goals, quality of life, all the things we've talked about before becomes even more important.

So bones are by far the most common site of metastasis in prostate cancer. Beyond controlling the cancer itself, what are your priorities when you're treating a patient with skeletal metastases? Are you looking at managing pain? Are you looking at trying to prevent fractures?

Wee: All the above. Again.

Mangels: Those and more.

Wee: So in castration-sensitive disease, the primary treatment is actually just using systemic therapy, ADT [androgen deprivation therapy] plus ARPI [androgen receptor pathway inhibitor], plus/minus chemo. The role of a bone-modifying agent such as a bisphosphonate like zoledronic acid [Reclast] or RANKL ligand like denosumab [Prolia] is reserved primarily for patients who have osteoporosis. So a bone scan would be helpful, bone density scan. And if someone has osteoporosis, that should be treated appropriately.

If a patient progresses to castration-resistant disease, there is an indication to give a bone-modifying agent to prevent a skeletal-related metastasis. So that's where the conversation comes into even if a patient doesn't have osteoporosis, if they have osseous metastases, there should be consideration to be giving a bone-modifying agent in castration-resistant disease. If there's a symptomatic spot that's causing a lot of trouble, that's a great time to also consider palliative radiation.

Mangels: Let's talk about radiation. When do you bring in radiation oncology and is the goal of the radiation to treat the tumor or to treat the pain or something else?

Wee: In metastatic prostate cancer, there's generally a few reasons. One, as we discussed previously, in de novo low-volume metastatic disease, primary prostatic radiation should be considered due to an overall survival benefit in STAMPEDE trial, but then also palliative radiation to specific spots if they're painful and metastasis-directed therapy.

So this is where the gray area comes in. So let's say someone has low-volume metastatic disease, just a couple of bone spots per se -- and we're getting this more often now that we have PSMA [prostate-specific membrane antigen] PET -- or a couple lymph nodes only. We had talked about previously how the standard of care metastatic disease is indefinite ADT, but what if you were able to zap all the spots of disease with radiation? Could you give a defined course of treatment to give a treatment-free interval? It's unclear the optimal duration and everything, but it's something we talk about with patients.

And anecdotally, some of these patients can get prolonged disease-free intervals where they don't have to be on treatment necessarily. And so that's something where it's shared decision-making with the patient.

Mangels: Are there particular patterns of metastatic spread or symptomatology or lab results, clinical findings that make you think, "Wow, I really need to think about whether this approach with this patient needs to change or not"?

Wee: I think there are two reasons why we would want to change. If one, the treatment regimen we're not doing is not working, or two, if it is not having manageable toxicity. Those are two reasons to change treatment.

Sometimes, this is not the most common situation, but sometimes despite the PSA being low, a patient could be clinically doing worse. They may be having more fatigue, more weight loss. That should be a red flag. At that time, usually I would re-image with conventional imaging if the PSA is low, because what you worry about in those situations is could this be differentiating into another process such as a neuroendocrine differentiation of prostate cancer or small cell neuroendocrine? And that's a lot more aggressive, at which point it needs to be managed differently with a lot more aggressive therapy sometimes.

Mangels: We talked a couple of seconds ago about bringing radiation oncology in, but that sort of opens the door to the importance of multidisciplinary care in these patients. Let's talk about that. You've got orthopedic oncology, I'm guessing, pain management, palliative care, rehab. Talk about how you coordinate all of those and involve all those and why they're important to be involved.

Wee: Absolutely. So radiation oncology is probably the most common one we work with, obviously. Palliative medicine with the symptom support, especially if there's pain involved because we can really improve patients' quality of life and oftentimes extend survival if we have good palliative care.

We're increasingly using our colleagues in nuclear medicine, both from a diagnostic standpoint with the PSMA PET scans as well as therapeutics with radioligand therapy. So this is one of the exciting parts of being a medical oncologist is the team-sport nature of this and how we can all work together to try to do what's best for the patient.

Mangels: Thanks so much for your insights, Dr. Wee. And thank you for joining us on Beyond Diagnosis, where we explore not just what physicians know, but how to effectively and compassionately share that knowledge with patients. See you next time.

来源:MedPage Today · medpagetoday.com